NCT06882499View on ClinicalTrials.gov

Stereotactic Ablative Body Radiotherapy (SABR) with Maintenance of Systemic Therapy Versus Physicians' Choice of Systemic Therapy for Oligoprogressive ER-positive, Her-2 Negative Breast Cancer II

NANot yet recruitingINTERVENTIONAL
Enrollment

74

Participants

Timeline

Start Date

May 1, 2025

Primary Completion Date

February 29, 2032

Study Completion Date

February 29, 2032

Conditions
Breast Cancer, MetastaticMetastatic Breast Cancer
Interventions
RADIATION

Stereotactic Ablative Radiotherapy

Stereotactic Ablative Radiotherapy

OTHER

Physician's choice of systemic treatment

Physician's choice of systemic therapy does not mandate a change in systemic therapy, however, SABR is not permitted for management in this arm

Sponsors
All Listed Sponsors
collaborator

Monash Health

OTHER

collaborator

Monash Medical Centre

OTHER

lead

Peter MacCallum Cancer Centre, Australia

OTHER